树突状细胞-细胞因子诱导杀伤细胞免疫治疗预计生存期低于3月的晚期恶性肿瘤患者  

Clinical Analysis of Patients Suffering from Advanced Malignancy with Survival Time Less Than 3 Months by DC-CIK Cells

作　　者：赵艳杰[1] 宋雨光[1] 张红梅[1] 姜妮[1] 朱希山[1] 王小利[1] 周心娜[1] 杨化兵 任军[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院肿瘤内科,北京100038

出　　处：《肿瘤防治研究》2014年第5期397-400,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨预计生存期小于3月的晚期肿瘤患者是否会从DC-CIK治疗中获益。方法对13例预计生存期小于3月、ECOG评分大于3的患者进行DC-CIK治疗,同时检测治疗前后T淋巴细胞亚群的变化,对比治疗前后ECOG评分的变化,统计OS,观察不良反应。结果末次DC-CIK治疗后两个月与治疗前对比,CD3+T细胞的增加和CD8+CD28-T细胞的减少差异有统计学意义。通过DC-CIK治疗11位患者ECOG评分得到改善,11位患者OS大于预计的3月,而且有7位患者至随访末仍然生存(均已大于6月),无明显不良反应发生。结论预计生存期小于3月的晚期肿瘤患者行DC-CIK治疗,是安全有效的。Objective To investigate whether the patients suffering from advanced malignancy with expected survival time less than 3 months will benefit from DC-CIK immunotherapeutic treatments. Methods Thirteen eligible patients with ECOG performance greater than 3 and expected survival time less than 3 months, were treated with DC-CIK immunotherapy. The level of peripheral blood T lymphocytes subsets were measured before and after DC-CIK infusions. The primary observations were the changes in ECOG performance, overall survival and adverse reactions. Results The levels of CD3+T cells were increased and CD8+CD28- T cells were reduced in two months after the last DC-CIK treatment, with statistical significance. Through the DC-DIK treatment, the ECOG performance improved in 11 patients and overall survival of the 11 patients was prolonged for 3 months. And there were 7 patients still alive at the end of follow-up(already more than 6 months). No severe adverse reactions occurred. Conclusion DC-CIK immunotherapy is effective and safe for advanced cancer patients with expected survival less than 3 months.

关 键 词：恶性肿瘤 免疫治疗 树突状细胞 细胞因子诱导杀伤细胞 

分 类 号：R730.5[医药卫生—肿瘤]